Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., Brock, K., De Lavallade, H., Craddock, C., Clark, R. E., Smith, M. L., Fletcher, R., Bishop, R., Milojkovic, D., & Yap, C. (2022). ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet, 9(2), e121–e132. http://access.bl.uk/ark:/81055/vdc_100150530190.0x000005